Enabling Life-Changing Therapies with Excellence and Commitment.
A Full Service CRO for Healthcare Innovation
Whether you are developing a small molecule or biologic, a vaccine or medical device, we have tailored solutions to move your research forward.
Learn more about Our History
Key Milestones of Corporate History
Tigermed Hong Kong
IPO in Shenzhen Stock Exchange (300347.SZ)
BRI Pharmaceutical & RMI Laboratories
Frontage IPO in HKSE (1521.HK)
Listed in HKEX (3347.HK)
DreamCIS IPO in Korea
Global expansion to Latin America, Africa and Middle East
Support of CanSino COVID-19 vaccine
Customer Recognition is Our
From our Customers
Best CRO Partnership Award | Merck
Global Supplier Award | Lilly
Outstanding Service Award | Merck
Best Startup Award | Hua Medicine
Best Strategic Collaboration Partner | Sinocelltech
Excellent Teamwork Award | Hutchison
Best Execution Partner Award | Betta Pharma
Best Strategic Partnership Award | Genorbio
Best SMO Company | Cancer Hospital of Peking University
From the Industry
2022 AAA in CNI ESG Rating by Shenzhen Stock Exchange
2021 FORTUNE The Future 50 Companies
2021 Frost & Sullivan “China Competitive Strategy Leadership”
2020 Frost & Sullivan "China CRO Customer Value Leadership"
2020 China Biopharmaceutical lndustry "Best Clinical CRO"
2019 Forbes Asia's 200 Best Under A Billion Companies
2019 Top 10 Most Valuable Pharma Company to lnvest
Recognized as 2019 Top 500 listed companies in China